IMPAM   23988
INSTITUTO DE INVESTIGACIONES EN MICROBIOLOGIA Y PARASITOLOGIA MEDICA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Importance of drug repositioning for the development of innovative therapies for tropical diseases
Autor/es:
TALEVI, ALAN; BELLERA, CAROLINA; SBARAGLINI, MARIA LAURA; ALBERCA, LUCAS; BALCAZAR, DARIO; FRACCAROLI, LAURA; VANRELL, M CRISTINA; CASSASA, FLORENCIA A; LABRIOLA, CARLOS; ALBA SOTO, CATALINA D.; ROMANO, PATRICIA S; CARRILLO, CAROLINA
Lugar:
Ciudad Autónoma de Buenos Aires. SAP lisana
Reunión:
Congreso; XXVII Reunión Anual. Sociedad Argentina de Protozoología.; 2015
Institución organizadora:
Sociedad Argentina de Protozoología.
Resumen:
IMPORTANCE OF DRUG REPOSITIONING FOR THE DEVELOPMENT OF INNOVATIVE THERAPIES FOR TROPICAL DISEASESAlan Talevi(1), Carolina Bellera(1), M Laura Sbaraglini(1), Lucas Alberca(1), Darío Balcázar(2), Laura Fraccaroli(2), M Cristina Vanrell(3), A Florencia Casassa(3), Carlos Labriola(4), Catalina D Alba Soto(5), Patricia S Romano(3), Carolina Carrillo (2).(1)Química Medicinal/Laboratorio de Investigación y Desarrollo de Bioactivos, Departamento de Ciencias Biológicas, UNLP,La Plata. (2)Instituto de Ciencia y Tecnología Dr. Cesar Milstein, Buenos Aires. (3)Instituto de Histología y Embriología -CONICET ? Facultad de Medicina, Universidad Nacional de Cuyo, Mendoza.(4)Instituto de Investigaciones Bioquímicas deBuenos Aires; 5IMPAM, Facultad de Medicina, UBA- CONICET, Buenos Aires. E-mail: atalevi@biol.unlp.edu.arThe term drug repositioning refers to the identification of second or further medical uses for known drugs, including approved, experimental, abandoned and discontinued ones. It is an efficient approach from the translational viewpoint:repositioned drugs required relatively low resource investment compared to de novo drugs, since usually a number of preclinical and clinical studies can be bypassed when investigating second medical uses, as they been done previously when studying the original therapeutic indication. Furthermore, the probability of surviving clinical trials is substantially higher for repurposed drug candidates than for novel ones. International organizations, including the US NIH, have recently launched funding programs to foster public-private consortiums oriented to drug repositioning. The approach could have aprominent role in the development of innovative treatments for rare and neglected diseases, including tropical parasitic diseases. In fact, most of the drugs for such conditions currently going through clinical trials are repositioned drugs. Here we will briefly describe different rational approaches to drug repositioning, with an emphasis on computer-guided approaches, and we will present some results from our research network using this strategy in the search of novel therapeutics for trypanosomatid infections, including cruzipain inhibitors and polyamine analogs.